← Back to Search

Ultrasound Therapy

Ultrasound Treatment for Burns (GE-MTEC Trial)

N/A
Recruiting
Led By David Armstrong, DPM, MD, PhD
Research Sponsored by General Electric Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 7, 14, 21 and 28

Summary

This trial is testing if using sound waves on the spleen can help heal burn wounds faster in patients with smaller burns. The sound waves are thought to reduce inflammation and improve immune cell function, speeding up recovery.

Who is the study for?
Adults aged 18+ with second-degree burns covering less than 20% of their body, who can consent to the study. They must not have an active wound infection or a high BMI (>30), and should not have had certain surgeries or conditions affecting the spleen, heart, blood, immune system; nor be on unstable steroids, other studies that could interfere, or have recent substance abuse.
What is being tested?
The trial is testing if pulsed ultrasound focused on the spleen can speed up healing in burn wounds. It's a small-scale study with half of the participants receiving real ultrasound treatment and half getting sham (fake) treatment to compare outcomes.
What are the potential side effects?
Since this is a pilot study primarily assessing safety and feasibility, detailed side effects are not provided but may include discomfort at the site of ultrasound application or potential unknown risks related to novel use of this technology.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 7, 14, 21 and 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 7, 14, 21 and 28 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of adverse device effects (ADEs)
Median time to re-epithelialization using advanced digital imaging
Secondary study objectives
Difference in groups in itch measured visual analog scale, (VAS)
Difference in groups in non-invasive perfusion measured visual analog scale, (VAS)
Difference in groups in pain measured visual analog scale, (VAS)
+4 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LOGIQ E10 ultrasound ActiveActive Control1 Intervention
The intervention condition will receive 10 minutes of splenic ultrasound daily.
Group II: LOGIQ E10 ShamPlacebo Group1 Intervention
The sham condition will consist of the ultrasound probe placed over the spleen with no energy applied.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for burns often focus on modulating the immune response and reducing inflammation to promote wound healing. For instance, Splenic Focused Pulsed Ultrasound Treatment aims to enhance wound healing by modulating the immune response and reducing inflammation, which can accelerate tissue repair and reduce scarring. This is crucial for burn patients as it can lead to faster recovery, reduced risk of infection, and improved functional and cosmetic outcomes. Other treatments, such as topical antimicrobials and dressings, work by preventing infection and maintaining a moist wound environment, which also supports the body's natural healing processes.

Find a Location

Who is running the clinical trial?

General Electric ResearchLead Sponsor
2 Previous Clinical Trials
46 Total Patients Enrolled
David Armstrong, DPM, MD, PhDPrincipal InvestigatorUSC Limb Preservation Consortium
7 Previous Clinical Trials
633 Total Patients Enrolled
~10 spots leftby Dec 2025